NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyraMir test for diagnosing thyroid cancer has received coverage from UnitedHealthcare.
With this coverage decision, ThyraMir is now covered for around 250 million patients nationwide, the company said.